Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, dose-escalation, phase I study to determine the maximum tolerated dose, recommended dose, pharmacokinetics, and pharmacodynamics of the proteosome inhibitor CEP 18770 given intravenously as single agent in patients with advanced solid tumours or non-Hodgkin's lymphomas

Next Previous
X
Search
Trial Profile

An open-label, dose-escalation, phase I study to determine the maximum tolerated dose, recommended dose, pharmacokinetics, and pharmacodynamics of the proteosome inhibitor CEP 18770 given intravenously as single agent in patients with advanced solid tumours or non-Hodgkin's lymphomas

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 May 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Delanzomib (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 21 May 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 21 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jan 2009 Planned end date changed from 1 Jun 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top